EFuturesCFO · Pharmaceutical Suite
Patent Cliff & Revenue Erosion
Model revenue at risk from patent expirations, generic/biosimilar entry timing, and quantify the impact of mitigation strategies including AG, LCM, and pipeline launches.
Executive Summary
8-Year Revenue Projection
Branded decline, pipeline ramp, and AG capture
Product Exposure
Mitigation Strategies
Executive Recommendations
Methodology
Generic erosion: Y1 60%, Y2 80%, Y3 90% (small molecule). Biosimilar erosion: 35%/year (slower uptake). AG captures specified % of generic market. LCM extends exclusivity by months. Pipeline revenue ramps linearly from Y3 to Y5 target. Industry data from IQVIA/EvaluatePharma benchmarks.